Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes
Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes
复制标题
DOI：
10.1016/j.ajo.2007.02.048
复制
发表时间：
2007-07-01
影响因子：
4.2
通讯作者：
Nohutcu, Ahmet F.
中科院分区：
文献类型：
--
作者：
Yanyali, Ates;Aytug, Banu;Nohutcu, Ahmet F.
目得：目的：报告玻璃体内注射贝伐单抗治疗糖尿病性黄斑水肿（DME）后视力（VA）和中心凹厚度（FT）的变化。设计：回顾性，非比较性，干预性病例系列。方法：回顾性分析10例11眼玻璃体内注射贝伐单抗治疗持续性DME患者的病历。这项回顾性研究纳入了尽管在我们的机构进行了先前的睫状体平坦部玻璃体切除术和内界膜去除术，但仍存在持续性DIVE的眼睛，并对DME进行了光学相干断层扫描（OCT）评估。所有眼睛每月接受三次贝伐珠单抗1.25 mg/0.05 ml玻璃体内注射。结果：基线时平均FT为408 +/- 77 μ m，3个月时为453 +/- 97 μ m，6个月时为454 +/- 101 μ m（P = .172）。糖尿病视网膜病变早期治疗研究（ETDRS）字母评分基线时平均为59 +/- 15（20/80），3个月时平均为59 +/-16（20/80），6个月时平均为57 +/- 15（20/80）（P = 0.398）。
PURPOSE: To report the visual acuity (VA) and foveal thickness (FT) changes after intravitreal bevacizumab for diabetic macular edema (DME) in previously vitrectomized eyes.DESIGN: Retrospective, noncomparative, interventional case series. METHODS: Medical records of 11 eyes of 10 patients who underwent intravitreal bevacizumab injection for persistent DME were reviewed. This retrospective study included eyes that had persistent DIVE despite prior pars plana vitrectomy with internal limiting membrane removal at our institution with optical coherence tomography (OCT) assessment of DME. All eyes received three intravitreal injections of bevacizumab 1.25 mg/0.05 ml monthly. RESULTS: Mean FT was 408 +/- 77 mu m at baseline, 453 +/- 97 mu m at three months, and 454 +/- 101 mu m at six months (P = .172). Mean Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores were 59 +/- 15 (20/80) at baseline, 5 9 16 (20/80) at three months, 57 +/- 15 (20/80) at six months (P = .398).CONCLUSION: No change in VA and FT was observed in the short-term after intravitreal bevacizumab for DME in previously vitrectornized eyes.